Enhanced antitumor activity mediated by human 4-1BB-engineered T cells

International Journal of Cancer

Volumn 133, Issue 12, 2013, Pages 2903-2913

  Daniel Meshulam, Inbal ^a   Horovitz Fried, Miryam ^a   Cohen, Cyrille J ^a  

^a BAR ILAN UNIVERSITY   (Israel)

Author keywords

4 1BB; immunotherapy; T cell engineering; T cells

Indexed keywords

CD137 ANTIGEN; CD137 LIGAND; GAMMA INTERFERON; PROTEIN BCL XL; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER;

4 IBB GENE; ADOPTIVE TRANSFER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL ENGINEERING; CELL MEDIATED CYTOTOXICITY; CELLULAR IMMUNITY; CHORIOALLANTOIS; CONTROLLED STUDY; CYTOKINE RELEASE; DNA MODIFICATION; GENE EXPRESSION; GENETIC MANIPULATION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; METASTATIC MELANOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRAL GENE DELIVERY SYSTEM;

4-1BB; IMMUNOTHERAPY; T-CELL ENGINEERING; T-CELLS;

4-1BB LIGAND; ANTIGENS, CD137; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; MELANOMA; RECEPTOR, NERVE GROWTH FACTOR; T-LYMPHOCYTES; VACCINATION;

EID: 84885668507     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28320     Document Type: Article

References (50)

1. Chattopadhyay K, Lazar-Molnar E, Yan Q, et al. Sequence, structure, function, immunity: structural genomics of costimulation. Immunol Rev 2009; 229: 356-86.
2. Ware CF,. The TNF receptor super family in immune regulation. Immunol Rev 2011; 244: 5-8.
3. Snell LM, Lin GH, McPherson AJ, et al. T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy. Immunol Rev 2011; 244: 197-217.
4. Pollok KE, Kim YJ, Hurtado J, et al. 4-1BB T-cell antigen binds to mature B cells and macrophages, and costimulates anti-mu-primed splenic B cells. Eur J Immunol 1994; 24: 367-74.
5. Futagawa T, Akiba H, Kodama T, et al. Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int Immunol 2002; 14: 275-86.
6. DeBenedette MA, Chu NR, Pollok KE, et al. Role of 4-1BB ligand in costimulation of T lymphocyte growth and its upregulation on M12 B lymphomas by cAMP. J Exp Med 1995; 181: 985-92.
7. Salih HR, Kosowski SG, Haluska VF, et al. Constitutive expression of functional 4-1BB (CD137) ligand on carcinoma cells. J Immunol 2000; 165: 2903-10.
8. Zhang H, Merchant MS, Chua KS, et al. Tumor expression of 4-1BB ligand sustains tumor lytic T cells. Cancer Biol Ther 2003; 2: 579-86.
9. Wang Q, Zhang P, Zhang Q, et al. Analysis of CD137 and CD137L expression in human primary tumor tissues. Croat Med J 2008; 49: 192-200.
10. Lee SW, Park Y, Song A, et al. Functional dichotomy between OX40 and 4-1BB in modulating effector CD8 T cell responses. J Immunol 2006; 177: 4464-72.
11. Shuford WW, Klussman K, Tritchler DD, et al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 1997; 186: 47-55.
12. Wen T, Bukczynski J, Watts TH,. 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function. J Immunol 2002; 168: 4897-906.
13. Hernandez-Chacon JA, Li Y, Wu RC, et al. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function. J Immunother 2011; 34: 236-50.
14. Lee HW, Park SJ, Choi BK, et al. 4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1. J Immunol 2002; 169: 4882-8.
15. Takahashi C, Mittler RS, Vella AT,. Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J Immunol 1999; 162: 5037-40.
16. Croft M,. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 2003; 3: 609-20.
17. Melero I, Shuford WW, Newby SA, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997; 3: 682-5.
18. Ju SA, Lee SC, Kwon TH, et al. Immunity to melanoma mediated by 4-1BB is associated with enhanced activity of tumour-infiltrating lymphocytes. Immunol Cell Biol 2005; 83: 344-51.
19. Narazaki H, Zhu Y, Luo L, et al. CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells. Blood 2010; 115: 1941-8.
20. Restifo NP, Dudley ME, Rosenberg SA,. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012; 12: 269-81.
21. Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17: 4550-7.
22. Robbins PF, Dudley ME, Wunderlich J, et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 2004; 173: 7125-30.
23. Merhavi-Shoham E, Haga-Friedman A, Cohen CJ,. Genetically modulating T-cell function to target cancer. Semin Cancer Biol 2012; 22: 14-22.
24. Topp MS, Riddell SR, Akatsuka Y, et al. Restoration of CD28 expression in CD28- CD8+ memory effector T cells reconstitutes antigen-induced IL-2 production. J Exp Med 2003; 198: 947-55.
25. Sun J, Dotti G, Huye LE, et al. T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms. Mol Ther 2010; 18: 2006-17.
26. Cohen CJ, Zheng Z, Bray R, et al. Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. J Immunol 2005; 175: 5799-808.
27. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126-9.
28. Haga-Friedman A, Horovitz-Fried M, Cohen CJ,. Incorporation of transmembrane hydrophobic mutations in the TCR enhance its surface expression and T cell functional avidity. J Immunol 2012; 188: 5538-46.
29. Bialer G, Horovitz-Fried M, Ya'acobi S, et al. Selected murine residues endow human TCR with enhanced tumor recognition. J Immunol 2010; 184: 6232-41.
30. Topalian SL, Solomon D, Rosenberg SA,. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 1989; 142: 3714-25.
31. Houghton AN, Real FX, Davis LJ, et al. Phenotypic heterogeneity of melanoma. Relation to the differentiation program of melanoma cells. J Exp Med 1987; 165: 812-29.
32. Vinay DS, Kwon BS,. Immunotherapy of cancer with 4-1BB. Mol Cancer Ther 2012; 11: 1062-70.
33. Thomas DA, Massague J,. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 2005; 8: 369-80.
34. Maus MV, Thomas AK, Leonard DG, et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol 2002; 20: 143-8.
35. Stephan MT, Ponomarev V, Brentjens RJ, et al. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med 2007; 13: 1440-9.
36. Friedman KM, Devillier LE, Feldman SA, et al. Augmented lymphocyte expansion from solid tumors with engineered cells for costimulatory enhancement. J Immunother 2011; 34: 651-61.
37. Pulle G, Vidric M, Watts TH,. IL-15-dependent induction of 4-1BB promotes antigen-independent CD8 memory T cell survival. J Immunol 2006; 176: 2739-48.
38. Milone MC, Fish JD, Carpenito C, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 2009; 17: 1453-64.
39. Cooper D, Bansal-Pakala P, Croft M,. 4-1BB (CD137) controls the clonal expansion and survival of CD8 T cells in vivo but does not contribute to the development of cytotoxicity. Eur J Immunol 2002; 32: 521-9.
40. Murphy JB,. Transplantability of tissues to the embryo of foreign species: its bearing on questions of tissue specificity and tumor immunity. J Exp Med 1913; 17: 482-93.
41. Niu L, Strahotin S, Hewes B, et al. Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice. J Immunol 2007; 178: 4194-213.
42. Mittler RS, Bailey TS, Klussman K, et al. Anti-4-1BB monoclonal antibodies abrogate T cell-dependent humoral immune responses in vivo through the induction of helper T cell anergy. J Exp Med 1999; 190: 1535-40.
43. Baessler T, Charton JE, Schmiedel BJ, et al. CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells. Blood 2010; 115: 3058-69.
44. Ascierto PA, Simeone E, Sznol M, et al. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol 2010; 37: 508-16.
45. Zhang P, Gao F, Wang Q, et al. Agonistic anti-4-1BB antibody promotes the expansion of natural regulatory T cells while maintaining Foxp3 expression. Scand J Immunol 2007; 66: 435-40.
46. Amos SM, Duong CP, Westwood JA, et al. Autoimmunity associated with immunotherapy of cancer. Blood 2011; 118: 499-509.
47. Moolten FL,. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986; 46: 5276-81.
48. Zhao Y, Wang QJ, Yang S, et al. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol 2009; 183: 5563-74.
49. Zhong XS, Matsushita M, Plotkin J, et al. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther 2010; 18: 413-20.
50. Deryugina EI, Quigley JP,. Chick embryo chorioallantoic membrane model systems to study and visualize human tumor cell metastasis. Histochem Cell Biol 2008; 130: 1119-30.